Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1973 2
1974 1
1976 1
1979 2
1981 2
1982 3
1984 1
1985 5
1986 7
1987 7
1988 6
1989 2
1990 9
1991 9
1992 9
1993 7
1994 11
1995 17
1996 13
1997 19
1998 18
1999 7
2000 10
2001 8
2002 7
2003 8
2004 5
2005 15
2006 5
2007 10
2008 9
2009 8
2010 9
2011 11
2012 8
2013 5
2014 6
2015 4
2016 6
2017 7
2018 9
2019 9
2020 12
2021 8
2022 11
2023 8
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

343 results

Results by year

Filters applied: . Clear all
Page 1
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM; TRAILBLAZER-ALZ 2 Investigators. Sims JR, et al. JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239. JAMA. 2023. PMID: 37459141 Free PMC article.
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS; GRADUATE I and II Investigators and the Gantenerumab Study Group. Bateman RJ, et al. N Engl J Med. 2023 Nov 16;389(20):1862-1876. doi: 10.1056/NEJMoa2304430. N Engl J Med. 2023. PMID: 37966285 Clinical Trial.
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF-06882961), an oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese adults with type 2 diabetes mellitus.
Ono R, Furihata K, Ichikawa Y, Nakazuru Y, Bergman A, Gorman DN, Saxena AR. Ono R, et al. Among authors: furihata k. Diabetes Obes Metab. 2023 Mar;25(3):805-814. doi: 10.1111/dom.14928. Epub 2022 Dec 19. Diabetes Obes Metab. 2023. PMID: 36433713 Free PMC article. Clinical Trial.
Physiologically-based pharmacokinetic model-based translation of OATP1B-mediated drug-drug interactions from coproporphyrin I to probe drugs.
Mochizuki T, Aoki Y, Yoshikado T, Yoshida K, Lai Y, Hirabayashi H, Yamaura Y, Rockich K, Taskar K, Takashima T, Chu X, Zamek-Gliszczynski MJ, Mao J, Maeda K, Furihata K, Sugiyama Y, Kusuhara H. Mochizuki T, et al. Among authors: furihata k. Clin Transl Sci. 2022 Jun;15(6):1519-1531. doi: 10.1111/cts.13272. Epub 2022 May 2. Clin Transl Sci. 2022. PMID: 35421902 Free PMC article.
Glycoprotein IIb-IIIa as an immunologic target.
Kunicki TJ, Furihata K, Nugent D. Kunicki TJ, et al. Among authors: furihata k. Curr Stud Hematol Blood Transfus. 1988;(54):44-63. doi: 10.1159/000415152. Curr Stud Hematol Blood Transfus. 1988. PMID: 3280255 Review. No abstract available.
DS-5670a, a novel mRNA-encapsulated lipid nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2: Results from a phase 2 clinical study.
Toyama K, Eto T, Takazawa K, Shimizu S, Nakayama T, Furihata K, Sogawa Y, Kumazaki M, Jonai N, Matsunaga S, Takeshita F, Yoshihara K, Ishizuka H. Toyama K, et al. Among authors: furihata k. Vaccine. 2023 Aug 31;41(38):5525-5534. doi: 10.1016/j.vaccine.2023.07.012. Epub 2023 Aug 14. Vaccine. 2023. PMID: 37586958 Free article. Clinical Trial.
Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug Interactions.
Mochizuki T, Zamek-Gliszczynski MJ, Yoshida K, Mao J, Taskar K, Hirabayashi H, Chu X, Lai Y, Takashima T, Rockich K, Yamaura Y, Fujiwara K, Mizuno T, Maeda K, Furihata K, Sugiyama Y, Kusuhara H. Mochizuki T, et al. Among authors: furihata k. Clin Pharmacol Ther. 2022 Jun;111(6):1315-1323. doi: 10.1002/cpt.2584. Epub 2022 Apr 11. Clin Pharmacol Ther. 2022. PMID: 35292967 Free PMC article.
343 results